ReviewWorld journal of gastroenterology2014
Alcohol and hepatocellular carcinoma: a review and a point of view.
Review in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Welding Fumes Exposure and the Risk of Head and Neck and Gastrointestinal Cancer: A Systematic Review and Meta-Analysis.La Medicina del lavoro · 2025Pooled it
- The Effects of Modest Alcohol Consumption on Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.Frontiers in medicine · 2021Pooled it
- Alcohol relapse and its predictors after liver transplantation for alcoholic liver disease: a systematic review and meta-analysis.BMC gastroenterology · 2019Pooled it
- Real impact of liver cirrhosis on the development of hepatocellular carcinoma in various liver diseases-meta-analytic assessment.Cancer medicine · 2019Pooled it
- Risk Factors for Hepatocellular Carcinoma in Latino Populations in Texas: A Scoping Review.International journal of molecular sciences · 2026Article
- Pathobiological Dictionary Defining Pathomics and Texture Features: Addressing Understandable AI Issues in Personalized Liver Cancer; Dictionary Version LCP1.0.Journal of imaging informatics in medicine · 2026Article
- Prevalence of hepatitis B virus infection among individuals with active tuberculosis attending selected Directly Observed Therapy (DOT) clinics in Oyo State, Nigeria.BMC infectious diseases · 2025Article
- Article
- MASH as an emerging cause of hepatocellular carcinoma: current knowledge and future perspectives.Molecular oncology · 2025Review
- Digestive cancers: mechanisms, therapeutics and management.Signal transduction and targeted therapy · 2025Review
- The impact of diabetes and social, biologic and behavioral determinants of health on liver cancer risk.Frontiers in endocrinology · 2025Article
- Liver disorders in substance abusers: Early identification.Hepatology forum · 2025Article
- What can claims data tell us about risk factors and survival of patients with hepatocellular carcinoma? Insights from a German population-based study.Frontiers in oncology · 2025Article
- Activation of pregnane X receptor sensitizes alcoholic steatohepatitis by transactivating fatty acid binding protein 4.Acta pharmaceutica Sinica. B · 2024Article
- Review
- Alcoholic Liver Disease in China: A Disease Influenced by Complex Social Factors That Should Not Be Neglected.Journal of clinical and translational hepatology · 2024Review
- Biological Activity of Natural and Synthetic Peptides as Anticancer Agents.International journal of molecular sciences · 2024Review
- Inflammatory Response in the Pathogenesis and Treatment of Hepatocellular Carcinoma: A Double-Edged Weapon.International journal of molecular sciences · 2024Review
- Alcohol-related liver disease.Hepatobiliary surgery and nutrition · 2024Article
- Alcoholic Liver Disease/Nonalcoholic Fatty Liver Disease Index at Diagnosis Is Associated with All-Cause Mortality during Follow-Up in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.Medicina (Kaunas, Lithuania) · 2024Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is well recognized that one cause of chronic liver disease and hepatocellular carcinoma (HCC) is alcohol consumption. Research in Italy and the United States concludes that the most common cause of HCC (responsible for 32% to 45% of HCC) is alcohol. It has recently been shown that a significant relationship between alcohol intake, metabolic changes, and hepatitis virus infection does exist. Alcohol may be a factor in the development of HCC via direct (genotoxic) and indirect mechanisms (cirrhosis). There is only one way of diagnosing HCC, which is early identification through surveillance, when curative treatments become possible. After stopping alcohol intake the risk of liver cancer decreases by 6% to 7% a year, and an estimated time period of 23 years is also needed. Therefore, surveillance is also important in former drinkers and, in our opinion, independently from the presence of compensated cirrhosis. In cases of very early stage (VES) and early stage with portal hypertension, liver transplantation is the optimal option; and in cases of associated disease, percutaneous ethanol injections, radiofrequency and microwave ablation are the ideal treatments. Despite the possibility of detecting microvascular invasion with HR, several studies and some randomized controlled trials revealed that overall survival and DSF rates in patients with VES HCC are much the same after ablation and HR. Therefore, ablation can be regarded as a first-line choice for patients with VES HCC. It is important to emphasize that the choice of treatment should be weighed carefully in the context of a multidisciplinary cancer team.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.